Literature DB >> 7854520

Optic neuritis: a population-based study in Olmsted County, Minnesota.

M Rodriguez1, A Siva, S A Cross, P C O'Brien, L T Kurland.   

Abstract

We reviewed the records of all patients with optic neuritis (ON) in Olmsted County, Minnesota, identified through the comprehensive records-linkage system at the Mayo Clinic, and identified 156 ON patients from 1935 to 1991 who had onset of the disease while residing in Olmsted County (incidence cases). Poisson regression analysis revealed that age, gender, and calendar year were associated with incidence. The annual age- and sex-adjusted incidence rate was 5.1 per 100,000 person-years from 1985 to 1991. On December 1, 1991, 128 patients with a documented history of ON resided in Olmsted County (prevalence cohort). The age- and sex-adjusted prevalence rate per 100,000 was 115. The average length of follow-up for the incidence cohort was 13.2 years. Life table analysis showed that 39% of the 95 patients with isolated ON in the incidence cohort had progressed to clinically definite multiple sclerosis (MS) by 10 years of follow-up, that 49% had by 20 years, 54% by 30 years, and 60% by 40 years. There was no difference in the risk of developing MS between men and women. The presence of venous sheathing (p = 0.044) and evidence for recurrent ON (p < 0.0001) were associated with an increased likelihood of developing MS. The estimated 25-year survival rate was 88.3% +/- 5.8% for the incidence cohort with isolated ON, compared with 83.9% for the general US population of similar age and sex.

Entities:  

Mesh:

Year:  1995        PMID: 7854520     DOI: 10.1212/wnl.45.2.244

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  74 in total

Review 1.  Physicians, subsequence and consequence.

Authors:  W I McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  CSF abnormalities can be predicted by VEP and MRI pathology in the examination of optic neuritis.

Authors:  Henrik Horwitz; Matilda Degn; Signe Modvig; Henrik B W Larsson; Benedikte Wanscher; Jette L Frederiksen
Journal:  J Neurol       Date:  2012-06-06       Impact factor: 4.849

Review 3.  Corticosteroids for treating optic neuritis.

Authors:  Robin L Gal; Satyanarayana S Vedula; Roy Beck
Journal:  Cochrane Database Syst Rev       Date:  2015-08-14

4.  Isolated optic neuritis and its prognosis for multiple sclerosis: a clinical and paraclinical study with evoked potentials. CSF examination and brain MRI.

Authors:  A Ghezzi; V Torri; M Zaffaroni
Journal:  Ital J Neurol Sci       Date:  1996-10

Review 5.  Corticosteroids for treating optic neuritis.

Authors:  S S Vedula; S Brodney-Folse; R L Gal; R Beck
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

6.  Correlation between full-field and multifocal VEPs in optic neuritis.

Authors:  Alexander Klistorner; Clare Fraser; Raymond Garrick; Stuart Graham; Hemamalini Arvind
Journal:  Doc Ophthalmol       Date:  2007-08-07       Impact factor: 2.379

Review 7.  Isolated, relapsing and progressive demyelinating diseases of the central nervous system.

Authors:  Axel Petzold
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

8.  Optic neuritis in different strains of mice by a recombinant HSV-1 expressing murine interleukin-2.

Authors:  Mandana Zandian; Raelene Belisle; Kevin R Mott; Steven Nusinowitz; Florence M Hofman; Homayon Ghiasi
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02-21       Impact factor: 4.799

9.  The incidence of clinically isolated syndrome in a multi-ethnic cohort.

Authors:  Annette Langer-Gould; Sonu M Brara; Brandon E Beaber; Jian L Zhang
Journal:  J Neurol       Date:  2014-04-29       Impact factor: 4.849

10.  Immune-mediated disorders among women carriers of fragile X premutation alleles.

Authors:  Tri Indah Winarni; Weerasak Chonchaiya; Tanjung Ayu Sumekar; Paul Ashwood; Guadalupe Mendoza Morales; Flora Tassone; Danh V Nguyen; Sultana M H Faradz; Judy Van de Water; Kylee Cook; Alyssa Hamlin; Yi Mu; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet A       Date:  2012-08-17       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.